All articles tagged with #cellular therapy
A woman with incurable HPV-related head and neck cancer in New Jersey experienced a remission after participating in a groundbreaking cellular therapy clinical trial at Rutgers Cancer Institute, which showed promising results for treating advanced cancers with a one-time engineered T-cell therapy.
The FDA has approved Amtagvi, the first cellular therapy for adult patients with unresectable or metastatic melanoma that has been previously treated with other therapies. Amtagvi is a tumor-derived autologous T cell immunotherapy composed of a patient’s own T cells, and it has shown promising results in clinical trials. However, patients receiving this treatment may experience severe adverse reactions, and close monitoring is necessary.
The FDA has approved Lantidra, the first cellular therapy for type 1 diabetes. Lantidra is an allogeneic pancreatic islet cellular therapy made from deceased donor pancreatic cells. Clinical studies have shown that some participants who received Lantidra did not need to administer insulin for more than 5 years. This therapy is intended for individuals with type 1 diabetes who struggle to control their blood sugar levels despite intensive management. However, Lantidra does come with potential side effects and requires the use of immunosuppressive medications. While this approval is a significant step towards alternative therapies for type 1 diabetes, it is not suitable for all patients due to its side effect profile and the need for ongoing immunosuppression.
The FDA has approved Lantidra, a cellular therapy made from deceased donor pancreatic cells, to help adults with Type 1 diabetes maintain their target blood glucose levels. Lantidra aims to replace the insulin-producing beta cells in the pancreas, potentially eliminating the need for daily injections or infusions of insulin. Clinical studies have shown that a significant number of participants did not need insulin for one to five years or more after receiving Lantidra infusions. However, there were some side effects and serious adverse reactions reported, so patients are advised to discuss the benefits and risks with their doctors.
The FDA has approved Lantidra, the first cellular therapy for the treatment of type 1 diabetes. Lantidra is made from deceased donor pancreatic cells and is intended for adults with type 1 diabetes who experience severe hypoglycemia despite intensive diabetes management. The therapy works by infusing allogeneic islet beta cells, which can produce enough insulin to potentially eliminate the need for daily insulin injections. However, adverse reactions such as nausea, fatigue, and abdominal pain were observed, and some patients had to discontinue immunosuppressive medications, resulting in the loss of islet cell function.